Recent News

• 02.21.2026 - Efficacy and Safety of Taletrectinib in Patients With ROS1+ NSCLC: Updated Safety Analysis From the Phase 2 TRUST-I and TRUST-II Studies
• 12.08.2025 - Subgroup Analysis of Japanese Patients in the Phase II Study of Taletrectinib in Patients with ROS1+ NSCLC: The Global TRUST-II Study
• 12.03.2025 - Phase 2, multicenter, randomized clinical study to evaluate the efficacy and safety of safusidenib in patients with high-grade isocitrate dehydrogenase 1 (IDH1)-mutant glioma

Recent Filings

• 02.10.2026 - 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 144 Report of proposed sale of securities
• 11.26.2025 - 8-K Current report
• 11.26.2025 - EX-99.1 EX-99.1
• 11.26.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.26.2025 - 144 Report of proposed sale of securities
• 11.25.2025 - 144 Report of proposed sale of securities